1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

23 Jul 2024
Admin
News Article

Zuellig Pharma Signs a 10-Year Commercialisation Partnership with Institut Allergosan

Zuellig Pharma signs a 10-year commercialisation partnership with Institut AllergoSan to bring leading probiotic brand OMNi-BiOTiC to key markets in Asia

Overview

Zuellig Pharma, a leading healthcare solutions company in Asia, announced that it has signed a 10-year commercialisation partnership with Austria-based Institut AllergoSan, a research and development company that specialises in products made from natural substances such as probiotic bacteria, plant extracts and minerals.

Partnership for OMNi-BiOTiC

Anita Frauwallner, founder and CEO of Institut AllergoSan (left) and John Graham, Group CEO, Zuellig Pharma (right) at the partnership signing ceremony to bring OMNi-BiOTiC to key markets in Asia.

Under the Partnership

Under this partnership, Zuellig Pharma will provide a wide spectrum of commercialisation support, including product registration, sales and marketing, and warehousing and distribution services to bring OMNi-BiOTiC, one of Institut AllergoSan's leading probiotic brands, to key markets in Asia.

Words from CEO: Zuellig Pharma

"Our consumer healthcare segment will be one of the key growth drivers in our business over the coming years and this partnership represents a significant step forward in our commitment to delivering innovative and accessible healthcare solutions to patients in Asia. With a fast-growing probiotics market in Asia, the comprehensive and tailored solutions offered through our commercialisation division, ZP Therapeutics, will help our partners expand their footprint to meet greater consumer demand for gut health products in this region.”
“Together with Institut AllergoSan, we will leverage our combined expertise to enhance the well-being of consumers and drive forward our mission of making healthcare more accessible,"" said John Graham, Group CEO, Zuellig Pharma.

Words from CEO: Institut AllergoSan

"We are dedicated to supporting consumers' pursuit of a healthier, more vital self and offer medically relevant probiotic supplements that target specific health needs and deliver clinically backed results. OMNi-BiOTiC is the top selling probiotic brand in all German-speaking markets in Europe such as Austria, Germany and Switzerland and we look forward to working closely with Zuellig Pharma to bring these innovative products to everybody in Asia who wants to promote an active, healthy life," adds Anita Frauwallner, founder and CEO of Institut AllergoSan.

Future launch- Zuellig Pharma plans to launch OMNi-BiOTiC in Indonesia, the Philippines and Taiwan in 2025, followed by other key markets thereafter.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve.
The company provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region.

About Institut AllergoSan

Institut AllergoSan, based in Graz, Austria, was founded in 1991 by a group of integrative doctors and pharmacists together with Anita Frauwallner, who is now the managing director.
Since then, the company has been focused on the scientific research and development of products made from natural substances such as probiotic bacteria, dietary fibres, micronutrients, and plant extracts.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!